Exclusive

Publication

Byline

Location

Japan Capital Spending Data Due On Monday

India, June 1 -- Japan will on Monday release Q1 figures for capital spending, highlighting a modest day for Asia-Pacific economic activity. In the previous three months, capex was down 0.2 percent on... Read More


XPeng May Vehicle Delivers Surges

India, June 1 -- XPeng Inc. (XPEV) delivered 33,525 smart electric vehicles in May 2025. This was a huge increase of 230% compared to the same month last year. The company also continued its strong pe... Read More


Li Auto May Vehicle Deliveries Up 16.7%

India, June 1 -- Li Auto Inc. (LI) announced that it delivered 40,856 vehicles in May 2025, representing a year-over-year increase of 16.7%. In late May, Li Auto began to roll out OTA update version ... Read More


Pfizer Reveals Phase 3 Results For Vepdegestrant In Advanced Breast Cancer Treatment

India, May 31 -- Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with e... Read More


AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial

India, May 31 -- AstraZeneca (AZN,AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated a s... Read More


Regeneron Unveils Detailed Phase 3 C-POST Trial Results For Libtayo In High-Risk CSCC Patients

India, May 31 -- Regeneron Pharmaceuticals Inc. (REGN) announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab)in patients with high-risk cutaneou... Read More


Phase III Study Shows Genentech's Itovebi Combo Cuts Death Risk By 30% In Advanced Breast Cancer

India, May 31 -- Genentech, a member of the Roche Group (RHHBY), announced positive final results from the overall survival analysis of the Phase III INAVO120 study. These data showed Itovebi (inavoli... Read More


Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms

India, May 31 -- Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA p... Read More


Teva Study Highlights Gaps In Tardive Dyskinesia Diagnosis And Treatment In LTC Facilities

India, May 31 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) ... Read More


U.S. Stocks Broadly Lower In Cautious Trade

India, May 30 -- U.S. stocks are turning in a weak performance on Friday amid renewed concerns over trade tensions, and a batch of mixed economic data. The major averages all are down in negative ter... Read More